Pharma giant Aspen says it welcomes a potential probe into alleged anti-competitive behavior.
This comes after the official opposition, the Democratic Alliance, last Wednesday said it would write to the Competition Commission and the Medicines Control Council to request that they investigate the market conduct of Aspen Pharmacare, the leading South African pharmaceutical company.
That call came after reports in the United Kingdom and South Africa detailing how staff at Aspen Pharmacare allegedly plotted to dispose of life-saving cancer medication in order to drive up its price across Europe.
In a statement issued on Monday, Aspen said it welcomed the “process and the opportunity to categorically set aside such allegations of anti-competitive behaviour”.
The company notes it is “committed to full and constructive engagement with the Competition Commission should it wish to pursue such an investigation”.
Full Content: Eyewitness News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
OpenAI Board Denies Receiving Formal Bid from Elon Musk
Feb 12, 2025 by
CPI
Thomas Kauper, Former DOJ Antitrust Leader, Dies at 89
Feb 12, 2025 by
CPI
BlackRock’s Acquisition of Preqin Secures UK Regulatory Approval
Feb 12, 2025 by
CPI
NFL Sued Over Bluesky Ban by Fans Citing Antitrust Violations
Feb 12, 2025 by
CPI
Warburg Pincus Strikes $1 Billion Deal to Acquire Vermont Information Processing
Feb 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon